

March 16, 2018



## **ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting**

SAN JOSE, Calif., March 16, 2018 /PRNewswire/ --ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early cancer detection study at the annual meeting of the American Association of Immunologists (AAI) in Austin, Texas. The meeting will be held May 4-8, 2018 and will be attended by physicians and scientists dedicated to understanding and advancing the field of immunology.

ITUS's proprietary Cchek™ technology combines immunophenotyping, or analysis of white blood cells, with artificial intelligence (AI) to detect the presence of solid tumor from a blood sample. ITUS utilizes flow cytometry for immunophenotyping by monitoring leukocytes (white blood cells) focusing on a recently discovered class of cells known as Myeloid Derived Suppressor Cells (MDSCs). These cells, as well as other myeloid and lymphoid cells, comprise the human immune system, and ITUS's Cchek™ monitors perturbations in the immune system to identify tumors. An Artificial Intelligence application known as a Neural Network is utilized to perform the analysis.

"We are pleased that our presentation was accepted for this conference, as our focus is on monitoring the immune system to catch cancer early, and this audience is focused on immunology. Blood bathes all organs of the body, and within it are the signals that indicate disease. For early cancer detection it has been hard to identify those signals because they are so rare. With our flow cytometry protocols coupled with Artificial Intelligence, we have demonstrated an excellent ability to identify the signals that distinguish tumor-bearing patients from healthy individuals," stated Dr. Amit Kumar, President and CEO of ITUS Corporation. "After this presentation, we will have presented our technology at four scientific conferences in four consecutive months. We will continue to expose our technology to the scientific community, the biotech industry, and to corresponding investors," added Dr. Kumar.

### **American Association of Immunologists (AAI)**

The American Association of Immunologists (AAI) ([www.aai.org](http://www.aai.org)) is a scientific society


headquartered in Rockville, MD and is an association of professionally trained scientists from all over the world dedicated to advancing the knowledge of immunology and its related disciplines, fostering the interchange of ideas and information among investigators, and addressing the potential integration of immunologic principles into clinical practice. The association serves its members by providing a center for the dissemination of information relevant to the field and its practices such as educational and professional opportunities, scientific meetings, membership-derived issues and opinions, and important funding and policy issues. AAI owns and publishes *The Journal of Immunology*, the largest and most highly cited journal in the field, as well as *ImmunoHorizons*, an open access, peer-reviewed journal dedicated to the science of immunology.

### **ITUS Corporation**

[ITUS](#), a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek<sup>TM</sup> platform, a series of non-invasive blood tests for the early detection of solid tumor-based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at [www.ITUScorp.com](http://www.ITUScorp.com).

**Forward-Looking Statements:** Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION<sup>TM</sup>

 View original content with multimedia <http://www.prnewswire.com/news-releases/itus-to-present-data-from-early-cancer-detection-study-utilizing-artificial-intelligence-at-the-american-association-of-immunologists-aaai-meeting-300615051.html>

SOURCE ITUS Corporation